Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France

References

• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis. 2013;19(4):566–73. doi:10.3201/eid1904.111799.
   PubMed Web of Science ®Google Scholar
• Acevedo R, Bai X, Borrow R, Caugant DA, Carlos J, Ceyhan M, Christensen H, Climent Y, De Wals P, Dinleyici EC, et al. The global meningococcal initiative meeting on prevention of meningococcal disease worldwide: epidemiology, surveillance, hypervirulent strains, antibiotic resistance and high-risk populations. Expert Rev Vaccines. 2019;18(1):15–30. doi:10.1080/14760584.2019.1557520.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Chan M-S, Maiden MC. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinform. 2004;5(1):86. doi:10.1186/1471-2105-5-86.
   PubMed Web of Science ®Google Scholar
• Borrow R, Taha M-K, Giuliani MM, Pizza M, Banzhoff A, Bekkat-Berkani R. Methods to evaluate serogroup B meningococcal vaccines: from predictions to real-world evidence. J Infect. 2020;81(6):862–72. doi:10.1016/j.jinf.2020.07.034.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35. doi:10.1016/S0140-6736(12)61961-8.
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O’Ryan ML, Valenzuela MT, Prado V, Vergara R, Munoz A, Toneatto D, Grana G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet. 2012;379(9816):617–24. doi:10.1016/S0140-6736(11)61713-3.
   PubMed Web of Science ®Google Scholar
• Vogel U, Taha M-K, Vazquez JA, Findlow J, Claus H, Stefanelli P, Caugant DA, Kriz P, Abad R, Bambini S, et al. Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis. 2013;13(5):416–25. doi:10.1016/S1473-3099(13)70006-9.
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Boccadifuoco G, Biolchi A, Ward J, Frasch C, Moxon ER, Stella M, Comanducci M, Bambini S, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490–95. doi:10.1073/pnas.1013758107.
   PubMed Web of Science ®Google Scholar
• Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Krizova P, et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine. 2019;37(7):991–1000. doi:10.1016/j.vaccine.2018.12.061.
   PubMed Web of Science ®Google Scholar
• Rodrigues CMC, Jolley KA, Smith A, Cameron JC, Feavers IM, Maiden MCJ. Meningococcal deduced vaccine antigen reactivity (MenDeVAR) Index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol. 2020;59(1). doi:10.1128/JCM.02161-20.
   PubMed Web of Science ®Google Scholar
• HCSP. Avis du HCSP relatif à l’utilisation du vaccin Bexsero (Novartis Vaccines and Diagnostics). 2013.
   Google Scholar
• Taha MK, Gaudelus J, Deghmane AE, and Caron F. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother . 2020;16(10):1–6.
   PubMed Web of Science ®Google Scholar
• Haute Autorité de Santé. Stratégie de vaccination pour la prévention des infections invasives à méningocoques: le sérogroupe B et la place de Bexsero®. 2021. http://www.has-sante.fr/upload/docs/application/pdf/2021-06/strategie_de_vaccination_pour_la_prevention_des_infections_invasives_a_meningocoques_le_serogroupe_b_et_la_place_de_bexsero.pdf.
   Google Scholar
• Parent Du Chatelet I, Deghmane AE, Antona D, Hong E, Fonteneau L, Taha MK, Levy-Bruhl D. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015. J Infect. 2017;74(6):564–74. doi:10.1016/j.jinf.2017.02.011.
   PubMed Web of Science ®Google Scholar
• Hong E, Bakhalek Y, Taha MK. Identification of Neisseria meningitidis by MALDI-TOF MS may not be reliable. Clin Microbiol Infect. 2019;25(6):717–22. doi:10.1016/j.cmi.2018.09.015.
   PubMed Web of Science ®Google Scholar
• Jolley KA, Maiden MC. Automated extraction of typing information for bacterial pathogens from whole genome sequence data: Neisseria meningitidis as an exemplar. Euro Surveill. 2013;18(4):20379. doi:10.2807/ese.18.04.20379-en.
   PubMedGoogle Scholar
• Plikaytis BD, Stella M, Boccadifuoco G, Detora LM, Agnusdei M, Santini L, Brunelli B, Orlandi L, Simmini I, Giuliani M, et al. Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol. 2012;19(10):1609–17. doi:10.1128/CVI.00202-12.
   PubMed Web of Science ®Google Scholar
• Cohen J. A coefficient of agreement for nominal scales. Edu Psychol Measur. 1960;20(1):37–46. doi:10.1177/001316446002000104.
   Web of Science ®Google Scholar
• Caron F, Du Chatelet IP, Leroy JP, Ruckly C, Blanchard M, Bohic N, Massy N, Morer I, Floret D, Delbos V, et al. From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis. 2011;11(6):455–63. doi:10.1016/S1473-3099(11)70027-5.
   PubMed Web of Science ®Google Scholar
• Frosi G, Biolchi A, Lo Sapio M, Rigat F, Gilchrist S, Lucidarme J, Findlow J, Borrow R, Pizza M, Giuliani MM, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine. 2013;31(43):4968–74. doi:10.1016/j.vaccine.2013.08.006.
   PubMed Web of Science ®Google Scholar
• Tzanakaki G, Hong E, Kesanopoulos K, Xirogianni A, Bambini S, Orlandi L, Comanducci M, Muzzi A, Taha M-K. Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol. 2014;14(1):111. doi:10.1186/1471-2180-14-111.
   PubMed Web of Science ®Google Scholar
• Deghmane AE, Haeghebaert S, Hong E, Jousset A, Barret AS, Taha MK. Emergence of new genetic lineage, ST-9316, of Neisseria meningitidis group W in Hauts-de-France region, France 2013-2018. J Infect. 2020;80(5):519–26. doi:10.1016/j.jinf.2020.01.020.
   PubMed Web of Science ®Google Scholar
• Tozer SJ, Smith HV, Whiley DM, Borrow R, Boccadifuoco G, Medini D, Serruto D, Giuliani MM, Stella M, and De Paola R, et al. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: concordant predictions between MATS and genetic MATS. Hum Vaccin Immunother. 2021;17(9):1–9.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Andrews N, Parikh SR, Campbell H, White J, Edelstein M, Bai X, Lucidarme J, Borrow R, Ramsay ME. Vaccination of infants with meningococcal group B vaccine (4CMenB) in England. N Engl J Med. 2020;382(4):309–17. doi:10.1056/NEJMoa1901229.
   PubMed Web of Science ®Google Scholar
• Parikh SR, Campbell H, Bettinger JA, Harrison LH, Marshall HS, Martinon-Torres F, Safadi MA, Shao Z, Zhu B, von Gottberg A, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483–98. doi:10.1016/j.jinf.2020.05.079.
   PubMed Web of Science ®Google Scholar